First Academies to Drive Global Healthcare Revolutions Launched in Wales
Wales has become the first country in the world to launch specialized Intensive Learning Academies (ILAs) that will deliver transformational training and support across preventative health, value-based health and care, and innovations in health and social care.
Welsh universities have created a range of flexible courses that include degree-level opportunities within these growing fields. They are open for professionals from the health and social care, and life sciences sectors across the globe to learn together.
Led by Swansea University and Bangor University, the ILAs are also delivering research and tailor-made consultancy services. This will support individual organizations to identify, develop and collaborate on innovative practices that will help to meet the challenges facing health and social care.
The three ILAs will commence activities across 2021, with each specializing in a subject identified as a key future growth area for the global health and social care markets:
- The Value-Based Health and Care Academy developed at Swansea University offers educational courses, research opportunities, and consultancy services for Value-Based Health and Care.
- With a focus on prevention, Bangor University’s ALPHAcademy will provide opportunities to support and develop leaders who are able to think with a cross sector and service perspective, and deliver change with firm knowledge and wide networks.
- The All-Wales Academy for Innovation in Health & Social Care — a collaboration between Swansea University, Cardiff and Vale University Health Board, Cardiff University, and the Bevan Commission — is focusing on innovation and transformation within health and social care.
All courses will welcome applicants working across global health, social care, and life sciences systems. There are ILA scholarships available for those working within the health, social care and third sector within Wales and internationally, and for those who wish to retrain to join the sector.
Applications are now open for the bespoke programs, with more information available on the Life Sciences Hub Wales website.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
